FIELD: chemistry.
SUBSTANCE: invention relates to compound of formula I in which R1 represents halogen, methoxy group or cyano group; each of Y1 and Y2 represents CH, and one or two from U, V, W and X represent N, and each remaining one represents CH, or in case X, cam also represent CRa, or Ra represents halogen; A represents CH2CH(OH), CH2CH(NH2), CH(OH)CH(NH2) or CH(NH2)CH2, B represents CH2CH2, CH2NH or CONH, and D represents CH2, or A represents CH(OH)CH2, and B represents CH2NH, N(R2)CO or CONH, and D represents CH2, or B represents N(R2a)CH2, and D represents CH(OH), or A represents CH(OH)CH(OH), B represents CH2NH or CONH and D represents CH2, or A represents CH2CH2, and B represents CH2CH2, CH2NR3, NHCO, CONR4, CH2O, COCH2 or CH2CH2NH, and D represents CH2, or B represents CH2NH, and D represents CO, or A also represents CH2CH2, B represents NR4bCH2 and D represents CH(OH), or A represents CH=CH, B represents CH2NR5 or CONR6, and D represents CH2, or A represents C≡C, B represents CH2NH and D represents CO, or A represents COCH2, B represents CONH and D represents CH2, or A represents CH2N(R7), and B represents CH2CH2, a D represents CH2, or B represents CH2CH(OH), a D represents CH(OH), or A represents NHCH2, and B represents CH2NH, a D represents CH2, or B represents CH2NH, a D represents CO, or A represents NHCO, B represents CH(R8)NH or CH2CH2, and D represents CH2, or A represents OCH2, B represents CH=CH or CONH, and D represents CH2; R2 represents (C1-C4)alkyl; R2a represents hydrogen; R3 represents hydrogen, CO-(CH2)p-COOR3', (CH2)p-COOR3, (C2-C5)acyl or amino(C1-C4)alkyl, or also R3 represents (C1-C4)alkyl, which can be one or two times substituted with hydroxygroup, p stands for integer number from 1 to 4, and R3 represents hydrogen or (C1-C4)alkyl; R4 represents hydrogen or (C1-C4)alkyl; R4b represents hydrogen; R5 represents hydrogen or (C2-C5)acyl; R6 represents hydrogen or (C1-C4)alkyl; R7 represents hydrogen or (C1-C4)alkyl, which can be one or two times substituted with group, independently selected from hydroxygroup and aminogroup, R8 represents hydrogen or (C1-C4)alkyl; E represents one of the following groups (a-a1) where Z represents CH or N, and Q represents O or S, or E represents phenyl group, which is one or two times substituted in meta- and/or para-position with substituents, each of which is independently selected from group, including halogen, (C1-C3)alkyl and trifluoromethyl; or pharmaceutically acceptable salt of such compound. Formula I compound or its pharmaceutically acceptable salt is applied for obtaining medication or pharmaceutical composition for prevention or treatment of bacterial infection.
EFFECT: derivatives of oxazolidine antibiotics for obtaining medication for treatment of bacterial infections.
15 cl, 2 tbl, 214 ex
Title | Year | Author | Number |
---|---|---|---|
OXAZOLIDINE ANTIBIOTICS | 2008 |
|
RU2470022C2 |
5-AMINOCYCLYLMETHYLOXAZOLIDIN-2-ONE DERIVATIVES | 2008 |
|
RU2492169C2 |
OXAZOLIDINONE DERIVATIVES | 2009 |
|
RU2501799C2 |
TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | 2009 |
|
RU2530884C2 |
OXAZOLIDINE ANTIBIOTICS | 2009 |
|
RU2516701C2 |
4-(1-AMINOETHYL)CYCLOHEXYLAMINE DERIVATIVES | 2007 |
|
RU2460723C2 |
ANTIBIOTIC DERIVATIVES OF 2-OXO-OXAZOLIDINE-3, 5-DIYL | 2012 |
|
RU2616609C2 |
APPLICATION OF OXOZALIDINON-CHYNOLYN HYBRID ANTIBIOTICS FOR TREATMENT OF ANTHRAX AND OTHER INFECTIONS | 2004 |
|
RU2351335C2 |
INHIBITOR CONTAINING A TRICYCLIC DERIVATIVE, A METHOD OF ITS PRODUCTION AND ITS USE | 2019 |
|
RU2800543C2 |
METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES BY CERAMIDE DERIVATIVES | 2008 |
|
RU2517345C9 |
Authors
Dates
2014-02-10—Published
2008-04-10—Filed